IFF gets creative in Brazil
This article was originally published in The Rose Sheet
Executive Summary
International Flavors & Fragrances launches a new 8,500-square-meter, four-floor R&D facility in Sao Paulo, Brazil. According to the March 19 release, the site can fully accommodate the firm's creative, technical and customer support teams, merging flavors and fragrances developers for "creative synergies" between the two wings of the business. Investment in Brazil is part of firm's strategy to strengthen its presence in Latin America and expand and modernize facilities across the globe, IFF says, noting that it opened a creative center in Shanghai, China last month. The new San Paulo facility "will help us better study and understand local consumer needs and preferences and how these affect and are affected by global trends," says Denis Ferenc, regional general manager of fragrances. Chairman and CEO Robert M. Amen adds: "IFF is dedicated to helping our customers grow their brands. To deliver on this, we must sustain our leadership in material science, creativity, and consumer insights. The new Sao Paulo Creative Center is another demonstration of this commitment.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.